Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-Lung02: volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer
2023-503298-39-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of volrustomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival in PD-L1 <1% and Overall survival in PD-L1 <1%. Planned start Jun 2024; status: authorised.
02
Drugs
volrustomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503298-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503298-39-00.